secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001493152-23-007900
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics reports FY2022 revenue of $34.2M, down 65% YoY; net loss $0.45/share
--------------------------------------------------------------------------------

- Revenue $34.2M, down from $97.9M in 2021 due to lower COVID-19 test demand.
- Net loss $14.2M ($0.45 diluted EPS) vs net income $36.7M ($1.23) prior year.
- Operating loss $27.0M, driven by lower revenue, goodwill impairment, R&D for Co-Dx PCR Home.
- Adjusted net income (excl. goodwill) $1.2M, or $0.04 per diluted share.
- Initiated clinical evaluations for Co-Dx PCR Home platform; cash $81.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000149315223007900/0001493152-23-007900-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000149315223007900/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-007900

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer